Cover Image
市場調查報告書

粉末定量噴霧吸入器:醫療設備的開發平台評估

Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2016

出版商 GlobalData 商品編碼 357851
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
粉末定量噴霧吸入器:醫療設備的開發平台評估 Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2016
出版日期: 2016年05月09日 內容資訊: 英文 72 Pages
簡介

本報告提供粉末定量噴霧吸入器相關之開發中產品調查,提供您各開發階段趨勢和產品的主要開發企業,現在進行中的臨床實驗,產業的近幾年趨勢等資訊。

第1章 目錄

第2章 簡介

  • 粉末定量噴霧吸入器概要

第3章 開發中的產品

  • 粉末定量噴霧吸入器 - 開發中產品:各開發階段
  • 粉末定量噴霧吸入器 - 開發中產品:各地區 (國家)
  • 粉末定量噴霧吸入器 - 開發中產品:各法規途徑
  • 粉末定量噴霧吸入器 - 開發中產品:各核准時期 (估計)
  • 粉末定量噴霧吸入器 - 持續中臨床實驗

第4章 粉末定量噴霧吸入器 - 正在開發的開發中產品:各企業

  • 粉末定量噴霧吸入器企業 - 開發中產品:各開發階段
  • 粉末定量噴霧吸入器 - 開發中產品:各開發階段

第5章 粉末定量噴霧吸入器 開發企業與產品概要

  • Acorda Therapeutics, Inc.
  • Adamis Pharmaceuticals Corporation
  • Advent Pharmaceuticals Pty Ltd
  • Aespira Ltd.
  • AKELA Pharma Inc. (Inactive)
  • Bayer HealthCare AG
  • Bespak Europe Ltd.
  • GlaxoSmithKline Plc
  • Hovione FarmaCiencia SA
  • MannKind Corporation
  • Nanotherapeutics, Inc.
  • Nektar Therapeutics
  • Novartis AG
  • OPKO Health, Inc.
  • Pharmaxis Limited
  • Respira Therapeutics, Inc.
  • Sandoz International GmbH
  • Sheffield Hallam University
  • 新日本科學
  • Teva Pharmaceutical Industries Ltd.
  • University of Kansas
  • University of Texas Medical Branch at Galveston

第6章 粉末定量噴霧吸入器 - 近幾年趨勢

第7章 附錄

目錄
Product Code: GDME0183EPD

GlobalData's Medical Devices sector report, "Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2016" provides an overview of Dry Powder Inhaler Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dry Powder Inhaler Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Dry Powder Inhaler Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Dry Powder Inhaler Devices Overview

3. Products under Development

  • 3.1. Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
  • 3.2. Dry Powder Inhaler Devices - Pipeline Products by Territory
  • 3.3. Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
  • 3.4. Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
  • 3.5. Dry Powder Inhaler Devices - Ongoing Clinical Trials

4. Dry Powder Inhaler Devices - Pipeline Products under Development by Companies

  • 4.1. Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
  • 4.2. Dry Powder Inhaler Devices - Pipeline Products by Stage of Development

5. Dry Powder Inhaler Devices Companies and Product Overview

  • 5.1. Acorda Therapeutics, Inc. Company Overview
    • 5.1.1. Acorda Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. Adamis Pharmaceuticals Corporation Company Overview
    • 5.2.1. Adamis Pharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. Advent Pharmaceuticals Pty Ltd Company Overview
    • 5.3.1. Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Aespira Ltd. Company Overview
    • 5.4.1. Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. AKELA Pharma Inc. (Inactive) Company Overview
    • 5.5.1. AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. Bayer HealthCare AG Company Overview
    • 5.6.1. Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. Bespak Europe Ltd. Company Overview
    • 5.7.1. Bespak Europe Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. GlaxoSmithKline Plc Company Overview
    • 5.8.1. GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. Hovione FarmaCiencia SA Company Overview
    • 5.9.1. Hovione FarmaCiencia SA Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. MannKind Corporation Company Overview
    • 5.10.1. MannKind Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11. Nanotherapeutics, Inc. Company Overview
    • 5.11.1. Nanotherapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12. Nektar Therapeutics Company Overview
    • 5.12.1. Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13. Novartis AG Company Overview
    • 5.13.1. Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14. OPKO Health, Inc. Company Overview
    • 5.14.1. OPKO Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15. Pharmaxis Limited Company Overview
    • 5.15.1. Pharmaxis Limited Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16. Respira Therapeutics, Inc. Company Overview
    • 5.16.1. Respira Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17. Sandoz International GmbH Company Overview
    • 5.17.1. Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18. Sheffield Hallam University Company Overview
    • 5.18.1. Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19. Shin Nippon Biomedical Laboratories, Ltd. Company Overview
    • 5.19.1. Shin Nippon Biomedical Laboratories, Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20. Teva Pharmaceutical Industries Ltd. Company Overview
    • 5.20.1. Teva Pharmaceutical Industries Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.21. University of Kansas Company Overview
    • 5.21.1. University of Kansas Pipeline Products & Ongoing Clinical Trials Overview
  • 5.22. University of Texas Medical Branch at Galveston Company Overview
    • 5.22.1. University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview

6. Dry Powder Inhaler Devices- Recent Developments

  • 6.1. Mar 30, 2016: 80 Years of Innovation and Success in Healthcare: Chiesi Reports Significant International Growth in 2015
  • 6.2. Mar 07, 2016: New Health Outcomes Data Reinforce Role of Device Selection and Peak Inspiratory Flow Rate in Treatment of COPD Patients
  • 6.3. Oct 20, 2015: GSK announces positive new data comparing Incruse Ellipta to tiotropium and glycopyrronium in patients with COPD
  • 6.4. Jun 16, 2015: Consort Medical announces final results

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
  • Table 2: Dry Powder Inhaler Devices - Pipeline Products by Territory
  • Table 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
  • Table 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
  • Table 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials
  • Table 6: Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
  • Table 7: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
  • Table 8: Acorda Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: CVT-301 Drug Delivery Device - Product Status
  • Table 10: CVT-301 Drug Delivery Device - Product Description
  • Table 11: CVT-427 Drug Delivery Device - Product Status
  • Table 12: CVT-427 Drug Delivery Device - Product Description
  • Table 13: Adamis Pharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 14: 3M Taper Dry Powder Inhaler - Product Status
  • Table 15: 3M Taper Dry Powder Inhaler - Product Description
  • Table 16: APC-5000 - Dry Powder Inhaler - Product Status
  • Table 17: APC-5000 - Dry Powder Inhaler - Product Description
  • Table 18: Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 19: g60 Dry Powder Inhaler - Product Status
  • Table 20: g60 Dry Powder Inhaler - Product Description
  • Table 21: Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 22: resQhaler - Product Status
  • Table 23: resQhaler - Product Description
  • Table 24: AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 25: Fentanyl TAIFUN Inhaler - Product Status
  • Table 26: Fentanyl TAIFUN Inhaler - Product Description
  • Table 27: Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 28: Ciprofloxacin Dry Powder Inhaler - Product Status
  • Table 29: Ciprofloxacin Dry Powder Inhaler - Product Description
  • Table 30: Bespak Europe Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 31: DEV610 - Product Status
  • Table 32: DEV610 - Product Description
  • Table 33: GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 34: Gemini Multi-Dose Combination Inhaler - Product Status
  • Table 35: Gemini Multi-Dose Combination Inhaler - Product Description
  • Table 36: Hovione FarmaCiencia SA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 37: XCaps - Product Status
  • Table 38: XCaps - Product Description
  • Table 39: MannKind Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 40: Dreamboat - Product Status
  • Table 41: Dreamboat - Product Description
  • Table 42: Nanotherapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 43: GelVac Intranasal Powder Vaccine Delivery System - Product Status
  • Table 44: GelVac Intranasal Powder Vaccine Delivery System - Product Description
  • Table 45: NanoGENT - Product Status
  • Table 46: NanoGENT - Product Description
  • Table 47: Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview
  • Table 48: Nektar Dry Powder Inhaler - Amikacin - Product Status
  • Table 49: Nektar Dry Powder Inhaler - Amikacin - Product Description
  • Table 50: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 51: Ultibro Breezhaler - Product Status
  • Table 52: Ultibro Breezhaler - Product Description
  • Table 53: Novartis AG - Ongoing Clinical Trials Overview
  • Table 54: Ultibro Breezhaler - The Effectiveness of Single Dose Ultibro Breezhaler (Indacaterol/Glycopyrronium) by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in Improving FEV1 and Dyspnea During Stable State of COPD
  • Table 55: OPKO Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 56: Inspiromatic - Product Status
  • Table 57: Inspiromatic - Product Description
  • Table 58: Pharmaxis Limited Pipeline Products & Ongoing Clinical Trials Overview
  • Table 59: Orbital Dry Powder Inhaler - Product Status
  • Table 60: Orbital Dry Powder Inhaler - Product Description
  • Table 61: Respira Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 62: Dry Powder Inhaler - Product Status
  • Table 63: Dry Powder Inhaler - Product Description
  • Table 64: Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 65: Solis Multi-Dose Dry Powder Inhaler - Product Status
  • Table 66: Solis Multi-Dose Dry Powder Inhaler - Product Description
  • Table 67: Unit-Dose Dry Powder Inhaler - Product Status
  • Table 68: Unit-Dose Dry Powder Inhaler - Product Description
  • Table 69: Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 70: Dry Powder Inhaler - Product Status
  • Table 71: Dry Powder Inhaler - Product Description
  • Table 72: Shin Nippon Biomedical Laboratories, Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 73: µco System - Product Status
  • Table 74: µco System - Product Description
  • Table 75: Teva Pharmaceutical Industries Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 76: Spiromax EU / mDPI US - Product Status
  • Table 77: Spiromax EU / mDPI US - Product Description
  • Table 78: University of Kansas Pipeline Products & Ongoing Clinical Trials Overview
  • Table 79: Dry Powder Inhaler - Product Status
  • Table 80: Dry Powder Inhaler - Product Description
  • Table 81: University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview
  • Table 82: Dry Powder Drug Delivery System - Product Status
  • Table 83: Dry Powder Drug Delivery System - Product Description
  • Table 84: Glossary

List of Figures

  • Figure 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
  • Figure 2: Dry Powder Inhaler Devices - Pipeline Products by Territory
  • Figure 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
  • Figure 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
  • Figure 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials
Back to Top